NorthWest Biotherapeutics Inc (NWBO)

[StonkMaster]

https://abc7ny.com/glioblastoma-brain-cancer-cold-spring-harbor-lab-long-island/12759592/?ex_cid=TA_WABC_TW&taid=63db07961b86500001accb8b&utm_campaign=trueAnthem:+New+Content+(Feed)&utm_medium=trueAnthem&utm_source=twitter

In Rhode Island, scientists at Lifespan Cancer Institute said they've developed a vaccine that could extend the lives of glioblastoma patients.

Researchers said in the Phase III trial, newly diagnosed patients treated with the vaccine survived for a median of 22.4 months from surgery and five-year survival was 13%.

Typically, according to Lifespan, patients live for only about 15 to 17 months from diagnosis with a five-year survival from diagnosis only about 5%.

"This is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma," Lifespan said. "(This is the) first time in nearly 30 years that a Phase III trial of any type of treatment has shown such survival extension in recurrent glioblastoma."